Targetable pathways for drug repurposing in gastric cancer

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Gastric cancer (GC) is a leading cause of cancer-related deaths globally, often diagnosed at advanced stages.
• Limited early symptoms and non-specific late-stage presentation contribute to poor prognosis and low survival rates.
• Current treatment options are insufficient, highlighting the need for innovative therapeutic strategies.

Purpose of the Study:

• To review critical molecular pathways implicated in gastric cancer (GC) development.
• To explore the potential of drug repurposing for targeting these pathways in GC.
• To identify promising avenues for novel and cost-effective GC treatments.

Main Methods:

• Literature review of scientific articles on gastric cancer pathways and drug repurposing.
• Analysis of key signaling pathways involved in GC pathogenesis.
• Identification of approved drugs with potential for repurposing against these pathways.

Main Results:

• Several pathways, including MAPK, PI3K/AKT/mTOR, and Wnt/β-catenin, are crucial in GC progression.
• Drug repurposing presents a viable strategy due to reduced costs and development timelines.
• Targeting these pathways with repurposed drugs offers a promising approach for new GC therapies.

Conclusions:

• Repurposing existing drugs to target key molecular pathways is a promising strategy for advancing gastric cancer treatment.
• Further research into drug repurposing can lead to more accessible and effective therapies for GC patients.
• This approach holds potential for improving survival rates and overcoming limitations of current GC treatments.